Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rifaximin Novel Formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Formulation 1 - Low Dose | EXPERIMENTAL | Rifaximin Formulation 1 Capsules |
| Formulation 1 Capsules - Mid Dose | EXPERIMENTAL | Rifaximin Formulation 1 Capsules |
| Formulation 1 Capsules - High Dose | EXPERIMENTAL | Rifaximin Formulation 1 Capsules |
| Formulation 1 Capsules - Max Dose | EXPERIMENTAL | Rifaximin Formulation 1 Capsules |
| Formulation 1 Capsules - Placebo | PLACEBO_COMPARATOR | Placebo Formulation 1 Capsules |
| Formulation 2 - Low Dose | EXPERIMENTAL | Rifaximin Formulation 2 Capsules |
| Formulation 2- Mid Dose | EXPERIMENTAL | Rifaximin Formulation 2 Capsules |
| Formulation 2 - High Dose | EXPERIMENTAL | Rifaximin Formulation 2 Capsules |
| Formulation 2 - Max Dose | EXPERIMENTAL | Rifaximin Formulation 2 Capsules |
| Formulation 2 - Placebo | PLACEBO_COMPARATOR | Placebo Formulation 2 Capsules |
| Formulation 3 - Low dose | EXPERIMENTAL | Rifaximin Formulation 3 Capsules |
| Formulation 3 - Mid dose | EXPERIMENTAL | Rifaximin Formulation 3 Capsules |
| Formulation 3 - High dose | EXPERIMENTAL | Rifaximin Formulation 3 Capsules |
| Formulation 3 - Max dose | EXPERIMENTAL | Rifaximin Formulation 3 Capsules |
| Formulation 3 - Placebo | PLACEBO_COMPARATOR | Placebo Formulation 3 Capsules |
| Name | Type | Description |
|---|---|---|
| Rifaximin Novel Formulation | DRUG | Rifaximin Novel Formulation |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * The participant has the ability and willingness to sign a written informed consent, is either male or female aged between 18 and 65 years, inclusive, at the time of informed consent, is in good general health, and has a body mass index (BMI) at least 18 kg/m2 and at most 34 kg...
Rifaximin Novel Formulation is an investigational small molecule developed by Bausch Health Companies Inc. (ticker BHC). It is a new version of rifaximin being studied in a Phase 1 clinical program. The specific therapeutic indications for this novel formulation have not been disclosed.
Rifaximin Novel Formulation is being developed by Bausch Health Companies Inc., which trades under the ticker BHC. The company is responsible for the clinical development of this asset.
Rifaximin Novel Formulation is in Phase 1 clinical development. It is an investigational product and has not been approved by the FDA. The Phase 1 program has completed one trial.
Rifaximin Novel Formulation has been evaluated in one completed Phase 1 trial, NCT04529811. This randomized, placebo-controlled study assessed the safety and pharmacokinetics of novel rifaximin formulations in 124 healthy volunteers in New Zealand. No active trials are currently listed for this asset.
The intended therapeutic use of Rifaximin Novel Formulation has not been disclosed. The completed Phase 1 trial was conducted in healthy volunteers to evaluate safety and pharmacokinetics, not in a patient population with a specific disease.